PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma

References

• Habra MA, Sukkari MA, Hasan A, Albousen Y, Elsheshtawi MA, Jimenez C, Campbell M, Karam JA, Graham PH, Hatia RI, et al. Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study. Int J Cancer. 2019 Jun 26. doi:10.1002/ijc.32534.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Dekkers O, Else T, Baudin E, Berruti A, de Krijger RR, Haak HR, Mihai R, Assie G, Terzolo M. European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2018 Jul 24;179:G1–G46. doi:10.1530/EJE-18-0608.
   PubMed Web of Science ®Google Scholar
• Long SE, Miller BS. Adrenocortical cancer treatment. Surg Clin North Am. 2019 Aug 1;99(4):759–771. doi:10.1016/j.suc.2019.04.012.
   PubMed Web of Science ®Google Scholar
• Jasim S, Habra MA. Management of adrenocortical carcinoma. Curr Oncol Rep. 2019 Feb 23;21(3):20. doi:10.1007/s11912-019-0773-7.
   PubMed Web of Science ®Google Scholar
• Puglisi S, Perotti P, Cosentini D, Roca E, Basile V, Berruti A, Terzolo M. Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options. Expert Rev Anticancer Ther. 2018;18(11):1125–1133. doi:10.1080/14737140.2018.1510325.
   PubMed Web of Science ®Google Scholar
• Creemers SG, Hofland LJ, Korpershoek E, Franssen GJH, van Kemenade FJ, de Herder WW, van Kemenade FJ. Future directions in the diagnosis and medical treatment of adrenocortical carcinoma. Endocr Relat Cancer. 2016 Jan;23(1):R43–69. doi:10.1530/ERC-15-0452.
   PubMed Web of Science ®Google Scholar
• Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G, Hammer G. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res. 2009 Jan 15;15(2):668–676. doi:10.1158/1078-0432.CCR-08-1067
   PubMed Web of Science ®Google Scholar
• Laurell C, Velázquez-Fernández D, Lindsten K, Juhlin C, Enberg U, Geli J, Höög A, Kjellman M, Lundeberg J, Hamberger B, et al. Transcriptional profiling enables molecular classification of adrenocortical tumours. Eur J Endocrinol. 2009 Jul;161(1):141–152. doi:10.1530/EJE-09-0068.
   PubMed Web of Science ®Google Scholar
• de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab. 2005 Mar 1;90(3):1819–1829. doi:10.1210/jc.2004-1075.
   PubMed Web of Science ®Google Scholar
• de Reyniès A, Assié G, Rickman DS, Tissier F, Groussin L, René-Corail F, Dousset B, Bertagna X, Clauser E, Bertherat J. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol. 2009 Mar;27(7):1108–1115. doi:10.1200/JCO.2008.18.5678.
   PubMed Web of Science ®Google Scholar
• Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario A, Else T, Knijnenburg T, Ciriello G, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016 May 9;29(5):723–736. doi:10.1016/j.ccell.2016.04.002.
   PubMed Web of Science ®Google Scholar
• Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, René-Corail F, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014 Jun;46(6):607–612. doi:10.1038/ng.2953.
   PubMed Web of Science ®Google Scholar
• Kerkhofs TMA, Ettaieb MHT, Hermsen IGC, Haak HR. Developing treatment for adrenocortical carcinoma. Endocr Relat Cancer. 2015 Dec;22(6):R325–338. doi:10.1530/ERC-15-0318.
   PubMed Web of Science ®Google Scholar
• De Martino MC, van Koetsveld PM, Feelders RA, Sprij-Mooij D, Waaijers M, Lamberts SWJ, de Herder WW, Colao A, Pivonello R, Hofland LJ. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. Endocr Relat Cancer. 2012 Jun;19(3):351–364. doi:10.1530/ERC-11-0270.
   PubMed Web of Science ®Google Scholar
• Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pöllinger A, Laubner K, Strasburger CJ, Hahner S, Müller -H-H, et al. Sunitinib in refractory adrenocortical carcinoma: A phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 2012 Oct;97(10):3495–3503. doi:10.1210/jc.2012-1419.
   PubMed Web of Science ®Google Scholar
• García-Donas J, Hernando Polo S, Guix M, Climent Duran MA, Méndez-Vidal MJ, Jiménez-Fonseca P, Mateos LL, Rodriguez-Moreno JF, Moreno F, Segura E, et al. Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011–03. J Clin Oncol. 2014 May 20;32(15_suppl):4588. doi:10.1200/jco.2013.31.15_suppl.4587
   Web of Science ®Google Scholar
• O’Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, Yang SX, Nguyen D, Balasubramaniam S, Fojo T. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab. 2014 Apr 1;99(4):1291–1297. doi:10.1210/jc.2013-2298.
   PubMed Web of Science ®Google Scholar
• Lerario AM, Worden FP, Ramm CA, Hasseltine EA, Stadler WM, Else T, Shah MH, Agamah E, Rao K, Hammer GD. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer. 2014 Aug;5(4):232–239. doi:10.1007/s12672-014-0182-1.
   PubMed Web of Science ®Google Scholar
• Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol [Internet]. 2017 Aug 23 [[accessed 2019 Apr 25]];8. doi:10.3389/fphar.2017.00561
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002 Aug;8(8):793–800. doi:10.1038/nm730.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293–12297. doi:10.1073/pnas.192461099.
   PubMed Web of Science ®Google Scholar
• Reiss KA, Forde PM, Brahmer JR. Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy. 2014;6(4):459–475. doi:10.2217/imt.13.166.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455–2465. doi:10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443–2454. doi:10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng S-L, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014 Nov 27;515(7528):558–562. doi:10.1038/nature13904.
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014 Oct 1;20(19):5064–5074. doi:10.1158/1078-0432.CCR-13-3271
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27;515(7528):568–571. doi:10.1038/nature13954.
   PubMed Web of Science ®Google Scholar
• Cavalcante L, Carneiro BA, Costa RLB, Chae YK, Rademaker A, Giles FJ. Preliminary results from a phase II study of nivolumab for patients with metastatic adrenocortical carcinoma (ACC). J Clin Oncol. 2017 Mar 1;35(7_suppl):96.
   PubMed Web of Science ®Google Scholar
• Habra MA, Campbell MT, Jimenez C, Karp D, Hong D, Subbiah V, Pant S, Painter J, Khan S, Bernatchez C, et al. Efficacy of pembrolizumab (MK-3475) in patients withadrenocortical carcinoma. J Immunother Cancer. 2017 Nov;5(Suppl 2), P424.
   Google Scholar
• Heery CR, O’Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marté JL, Lepone LM, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18(5):587–598. doi:10.1016/S1470-2045(17)30239-5
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Hoimes C, Zarwan C, Wong DJ, Bauer S, Claus R, Wermke M, Hariharan S, von Heydebreck A, Kasturi V, et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer. 2018 Dec;6(1):111. doi:10.1186/s40425-018-0424-9.
   PubMed Web of Science ®Google Scholar
• Cosentini D, Grisanti S, Dalla Volta A, Laganà M, Fiorentini C, Perotti P, Sigala S, Berruti A. Immunotherapy failure in adrenocortical cancer: where next? Endocr Connect. 2018 Oct 30;7(12):E5–8. doi:10.1530/EC-18-0398.
   PubMed Web of Science ®Google Scholar
• Fiorentini C, Grisanti S, Cosentini D, Abate A, Rossini E, Berruti A, Sigala S. Molecular drivers of potential immunotherapy failure in adrenocortical carcinoma. J Oncol. 2019;2019:6072863. doi:10.1155/2019/6072863.
   PubMed Web of Science ®Google Scholar
• Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007 Apr 1;13(7):2151–2157. doi:10.1158/1078-0432.CCR-06-2746.
   PubMed Web of Science ®Google Scholar
• Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005 Apr 15;11(8):2947–2953. doi:10.1158/1078-0432.CCR-04-1469.
   PubMed Web of Science ®Google Scholar
• Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003 Oct 1;63(19):6501–6505.
   PubMed Web of Science ®Google Scholar
• Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15;13(6):1757–1761. doi:10.1158/1078-0432.CCR-06-2599.
   PubMed Web of Science ®Google Scholar
• Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17174–17179. doi:10.1073/pnas.0406351101.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360–3365. doi:10.1073/pnas.0611533104.
   PubMed Web of Science ®Google Scholar
• Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013 Jan 1;73(1):128–138. doi:10.1158/0008-5472.CAN-12-2606.
   PubMed Web of Science ®Google Scholar
• Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Slobec I, Eppenberger-Castori S, Tzankov A, Rosso R, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer Oxf Engl 1990. 2013 Jun;49(9), 2233–2242. doi:10.1016/j.ejca.2013.02.015
   PubMed Web of Science ®Google Scholar
• Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med. 2013 Aug 28;5(200):200ra116. doi:10.1126/scitranslmed.3006504.
   PubMed Web of Science ®Google Scholar
• Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R, Weller M, Wiendl H. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 2003 Nov 1;63(21):7462–7467.
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Mamessier E, Pantaleo MA, Astolfi A, Ostrowski J, Birnbaum D. PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology [Internet]. 2015 Feb 3 [accessed 2019 May 12];4(5). doi:10.1080/2162402X.2014.1002729
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Perrot D, Leroux A, Collin F, Le Cesne A, Coindre J-M, Blay J-Y, Birnbaum D, Mamessier E. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncoimmunology. 2017;6(3):e1278100. doi:10.1080/2162402X.2016.1278100.
   PubMed Web of Science ®Google Scholar
• Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Turrini O, Raoul J-L, Delpero J-R, Moutardier V, Birnbaum D, et al. Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget. 2016 01;7(44):71198–71210. doi:10.18632/oncotarget.11685
   PubMedGoogle Scholar
• Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L, Viens P, Birnbaum D, Van Laere S. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget. 2015 May 30;6(15):13506–13519. doi:10.18632/oncotarget.3642
   PubMedGoogle Scholar
• Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015 Mar 10;6(7):5449–5464. doi:10.18632/oncotarget.3216
   PubMedGoogle Scholar
• Fay AP, Signoretti S, Callea M, Telό GH, McKay RR, Song J, Carvo J, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, et al. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer [Internet]. 2015 Feb 17 [[accessed 2019 Apr 26]];3. doi:10.1186/s40425-015-0047-3
   PubMed Web of Science ®Google Scholar
• Palmer C, Diehn M, Alizadeh AA, Brown PO. Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics. 2006 May 16;7(1):115. doi:10.1186/1471-2164-7-115.
   PubMed Web of Science ®Google Scholar
• Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6994–6999. doi:10.1073/pnas.0912708107
   PubMed Web of Science ®Google Scholar
• Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015 Jan 15;160(1–2):48–61. doi:10.1016/j.cell.2014.12.033.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013 Oct 17;39(4):782–795. doi:10.1016/j.immuni.2013.10.003
   PubMed Web of Science ®Google Scholar
• Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig J Tech Methods Pathol. 2014 Jan;94(1):107–116. doi:10.1038/labinvest.2013.130.
   PubMed Web of Science ®Google Scholar
• Gadiot J, Hooijkaas AI, Kaiser ADM, van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer. 2011 May 15;117(10):2192–2201. doi:10.1002/cncr.25747.
   PubMed Web of Science ®Google Scholar
• Rimm D, Schalper K, Pusztai L. Unvalidated antibodies and misleading results. Breast Cancer Res Treat. 2014 Sep;147(2):457–458. doi:10.1007/s10549-014-3061-0.
   PubMed Web of Science ®Google Scholar
• Mamessier E, Birnbaum DJ, Finetti P, Birnbaum D, Bertucci F. CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors. Ann Transl Med [Internet]. 2018 Feb [accessed 2019 May 30];6(3). doi:10.21037/atm.2017.11.26
   PubMed Web of Science ®Google Scholar
• Li Y, Bian X, Ouyang J, Wei S, He M, Luo Z. Nomograms to predict overall survival and cancer-specific survival in patients with adrenocortical carcinoma. Cancer Manag Res. 2018;10:6949–6959. doi:10.2147/CMAR.S187169.
   PubMed Web of Science ®Google Scholar
• Morimoto R, Satoh F, Murakami O, Suzuki T, Abe T, Tanemoto M, ABE M, URUNO A, ISHIDOYA S, ARAI Y, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J. 2008;55(1):49–55. doi:10.1507/endocrj.K07-079.
   PubMed Web of Science ®Google Scholar
• Bagante F, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. J Surg Oncol. 2015 Aug;112(2):164–172. doi:10.1002/jso.23982.
   PubMed Web of Science ®Google Scholar
• Roufas C, Chasiotis D, Makris A, Efstathiades C, Dimopoulos C, Zaravinos A. The expression and prognostic impact of immune cytolytic activity-related markers in human malignancies: a comprehensive meta-analysis. Front Oncol. 2018;8:27. doi:10.3389/fonc.2018.00027.
   PubMed Web of Science ®Google Scholar
• Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014 May 15;20(10):2773–2782. doi:10.1158/1078-0432.CCR-13-2702
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013 Jul;1(1):54–63. doi:10.1158/2326-6066.CIR-13-0034.
   PubMed Web of Science ®Google Scholar
• Furusawa A, Reiser J, Sadashivaiah K, Simpson H, Banerjee A. Eomesodermin increases survival and IL-2 responsiveness of tumor-specific CD8+ T cells in an adoptive transfer model of cancer immunotherapy. J Immunother Hagerstown Md 1997. 2018 Mar;41(2):53–63.
   Google Scholar
• Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One. 2014 Feb 14;9(2):e88557. doi:10.1371/journal.pone.0088557.
   PubMed Web of Science ®Google Scholar
• Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostat Oxf Engl. 2003 Apr;4(2):249–264. doi:10.1093/biostatistics/4.2.249.
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Simeone I, Hendrickx W, Wang E, Marincola FM, Viens P, Mamessier E, Ceccarelli M, Birnbaum D, et al. The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. Br J Cancer. 2018 Nov;119(11):1383–1391. doi:10.1038/s41416-018-0309-1.
   PubMed Web of Science ®Google Scholar
• Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989 Mar;13(3):202–206.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005 Aug 22;93(4):387–391. doi:10.1038/sj.bjc.6602678.
   PubMed Web of Science ®Google Scholar